• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

    4/30/25 6:00:00 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBYI alert in real time by email

    ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ:PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designed to block human epidermal growth factor receptor 2 (HER2) in order to treat and limit breast cancer metastasis.

    Under the agreement, Er-Kim is appointed as the distribution partner for NERLYNX in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, and Uzbekistan.

    NERLYNX is a prescription medicine used alone to treat adults with early-stage HER2-positive breast cancer and who have previously been treated with trastuzumab-based therapy. NERLYNX is also approved for use with a medicine called capecitabine to treat adults with HER2-positive breast cancer that has spread to other parts of the body (metastatic) and who have received 2 or more anti-HER2 therapy medicines for metastatic breast cancer.

    According to the International Agency for Research on Cancer (IARC), globally, breast cancer is the most common cancer type among women and the second most common cancer type overall. An estimated 2.3 million new breast cancer cases and 670,000 breast cancer-related deaths occurred worldwide in 2022. However, the burden of breast cancer is not evenly distributed across different world regions.

    "While breast cancer affects individuals globally, treatment availability varies considerably across regions," said Cem Zorlular, Chief Executive Officer of Er-Kim. "That is why we are pleased to be working with Puma Biotechnology to support access to NERLYNX in Russia and most of the Commonwealth of Independent States (CIS) for patients with early-stage breast cancer. Er-Kim has a long history of providing treatments in the EMEA region, particularly in women's health."

    About Er-Kim

    Established in 1981, Er-Kim stands at the forefront of biopharmaceutical innovation, partnering with over 40 global leaders to revolutionize patient care in key international markets. Our pioneering business models, tailored for sustainability and flexibility, have positioned us as a full-service solution, extending our reach to over 600 million patients through our fully owned affiliates. With a dedicated team of over 280 professionals worldwide and revenues exceeding EUR 260M, Er-Kim is not just a partner but a trailblazer in healthcare, continually setting new standards in commercialization and patient access. For more information, please visit http://www.er-kim.com/.

    About Puma Biotechnology

    Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early- stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

    In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.

    Media contact:

    Rosalia Scampoli

    Marketcom PR

    Tel: (914) 815-1465

    [email protected]



    Primary Logo

    Get the next $PBYI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBYI

    DatePrice TargetRatingAnalyst
    9/28/2021$11.00Neutral → Buy
    Citigroup
    9/28/2021Neutral → Buy
    Citigroup
    8/6/2021$13.00 → $6.00Sector Perform
    RBC Capital
    8/6/2021$9.00 → $8.00Sell
    Goldman Sachs
    More analyst ratings

    $PBYI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Nougues Maximo F was granted 61,456 shares, increasing direct ownership by 40% to 213,751 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      2/11/25 6:58:40 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Ludwig Jeffrey Jerome was granted 47,841 shares, increasing direct ownership by 44% to 156,792 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      2/11/25 6:55:59 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Hunt Douglas M was granted 48,117 shares, increasing direct ownership by 39% to 172,711 units (SEC Form 4)

      4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

      2/11/25 6:53:52 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Puma Biotech. upgraded by Citigroup with a new price target

      Citigroup upgraded Puma Biotech. from Neutral to Buy and set a new price target of $11.00

      9/28/21 7:42:41 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology upgraded by Citigroup

      Citigroup upgraded Puma Biotechnology from Neutral to Buy

      9/28/21 4:54:51 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Puma Biotechnology with a new price target

      RBC Capital reiterated coverage of Puma Biotechnology with a rating of Sector Perform and set a new price target of $6.00 from $13.00 previously

      8/6/21 10:44:06 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PBYI
    SEC Filings

    See more

    $PBYI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, April 1, 2025 a

      5/6/25 5:15:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

      ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ:PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designed to block human epidermal growth factor receptor 2 (HER2) in order to treat and limit breast cancer metastasis. Under the agreement, Er-Kim is appointed as the distribution partner for NERLYNX in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, and Uzb

      4/30/25 6:00:00 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Inc filed SEC Form 8-K: Leadership Update

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/9/25 8:57:31 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Puma Biotechnology Inc

      10-Q - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/8/25 4:41:37 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/8/25 4:20:43 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Puma Biotechnology Inc

      SC 13G - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      3/29/24 10:40:57 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

      SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      2/14/24 8:19:11 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

      SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

      2/13/24 5:12:15 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Financials

    Live finance-specific insights

    See more
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of

      4/24/25 4:11:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat

      2/27/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBYI
    Leadership Updates

    Live Leadership Updates

    See more
    • Puma Biotechnology to Join Russell 3000 Index

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor

      5/28/24 9:00:00 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

      Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and

      11/17/22 4:15:00 PM ET
      $EPIX
      $PBYI
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff

      Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper

      8/15/22 5:00:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care